The Wall Street Journal96d agoneutral
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift RevenueNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Barrons.com96d agoneutral
Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger StoryInvestor's Business Daily114d agoneutral
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.The Wall Street Journal137d agoneutral
New Drugs Are Replacing Chemo for Aggressive Breast CancerBarrons.com164d agoneutral
S&P 500, Nasdaq Rise to Another Record. Software Strikes Back.Insider Monkey167d agoneutral
Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology PortfolioSimply Wall St.183d agoneutral
Stronger HIV Pipeline And Acquisition Charges Might Change The Case For Investing In Gilead Sciences (GILD)MT Newswires184d agoneutral
Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley SaysThe Wall Street Journal185d agoneutral
Gilead Sciences Expects Loss This Year on Acquired R&D ExpensesInvestor's Business Daily185d agoneutral
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy